These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10873996)

  • 1. Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin.
    Hardus P; Verduin WM; Postma G; Stilma JS; Berendschot TT; van Veelen CW
    Br J Ophthalmol; 2000 Jul; 84(7):788-90. PubMed ID: 10873996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication.
    Hardus P; Verduin WM; Postma G; Stilma JS; Berendschot TT; van Veelen CW
    Epilepsia; 2000 May; 41(5):581-7. PubMed ID: 10802764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No reversion in vigabatrin-associated visual field defects.
    Nousiainen I; Mäntyjärvi M; Kälviäinen R
    Neurology; 2001 Nov; 57(10):1916-7. PubMed ID: 11723291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects.
    Kälviäinen R; Nousiainen I; Mäntyjärvi M; Nikoskelainen E; Partanen J; Partanen K; Riekkinen P
    Neurology; 1999 Sep; 53(5):922-6. PubMed ID: 10496247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of electrophysiology results in patients with epilepsy and vigabatrin associated visual field loss.
    Hardus P; Verduin WM; Berendschot TT; Kamermans M; Postma G; Stilma JS; van Veelen CW
    Acta Ophthalmol Scand; 2001 Apr; 79(2):169-74. PubMed ID: 11284756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is visual field constriction in epilepsy patients treated with vigabatrin reversible?
    Schmidt T; Rüther K; Jokiel B; Pfeiffer S; Tiel-Wilck K; Schmitz B
    J Neurol; 2002 Aug; 249(8):1066-71. PubMed ID: 12195456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.
    Kjellström U; Lövestam-Adrian M; Andréasson S; Ponjavic V
    Doc Ophthalmol; 2008 Sep; 117(2):93-101. PubMed ID: 18188629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Vigabatrin: balancing effectiveness vs. (irreversible) visual field loss as a side effect].
    Hardus P; Engelsman M; van Veelen CW; Stilma JS
    Ned Tijdschr Geneeskd; 2000 Oct; 144(43):2066-9. PubMed ID: 11072511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual field loss associated with vigabatrin: quantification and relation to dosage.
    Hardus P; Verduin WM; Engelsman M; Edelbroek PM; Segers JP; Berendschot TT; Stilma JS
    Epilepsia; 2001 Feb; 42(2):262-7. PubMed ID: 11240600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual field and electrophysiological abnormalities due to vigabatrin.
    van der Torren K; Graniewski-Wijnands HS; Polak BC
    Doc Ophthalmol; 2002 Mar; 104(2):181-8. PubMed ID: 11999625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal.
    Fledelius HC
    Acta Ophthalmol Scand; 2003 Feb; 81(1):41-6. PubMed ID: 12631018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of visual field loss over ten years in individuals taking vigabatrin.
    Clayton LM; Stern WM; Newman WD; Sander JW; Acheson J; Sisodiya SM
    Epilepsy Res; 2013 Aug; 105(3):262-71. PubMed ID: 23541931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual field constriction on vigabatrin.
    Prescrire Int; 2000 Feb; 9(45):210-1. PubMed ID: 11503799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electro-ophthalmological recovery after withdrawal from vigabatrin.
    Graniewski-Wijnands HS; van der Torren K
    Doc Ophthalmol; 2002 Mar; 104(2):189-94. PubMed ID: 11999626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual field constriction is not limited to children treated with vigabatrin.
    Wohlrab G; Boltshauser E; Schmitt B; Schriever S; Landau K
    Neuropediatrics; 1999 Jun; 30(3):130-2. PubMed ID: 10480207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visual fields at school-age in children treated with vigabatrin in infancy.
    Gaily E; Jonsson H; Lappi M
    Epilepsia; 2009 Feb; 50(2):206-16. PubMed ID: 19215279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Objective Derivation of the Morphology and Staging of Visual Field Loss Associated with Long-Term Vigabatrin Therapy.
    Wild JM; Smith PEM; Knupp C
    CNS Drugs; 2019 Aug; 33(8):817-829. PubMed ID: 31250314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visual field defects associated with vigabatrin therapy.
    Lawden MC; Eke T; Degg C; Harding GF; Wild JM
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):716-22. PubMed ID: 10567485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the risk of visual field loss arising from long-term exposure to the antiepileptic drug vigabatrin: a cross-sectional approach.
    Wild JM; Fone DL; Aljarudi S; Lawthom C; Smith PE; Newcombe RG; Lewis GD
    CNS Drugs; 2013 Oct; 27(10):841-9. PubMed ID: 23990316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is reduced ornithine-δ-aminotransferase activity the cause of vigabatrin-associated visual field defects?
    Sorri I; Brigell MG; Mályusz M; Mahlamäki E; de Meynard C; Kälviäinen R
    Epilepsy Res; 2010 Nov; 92(1):48-53. PubMed ID: 20850272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.